Commentary on "Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery." Atorvastatin's effect in Alzheimer's dementia (LEADe) study

Alzheimer's and Dementia

Volumn 2, Issue 4, 2006, Pages 282-283

  Hey Hadavi, Judith ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ATORVASTATIN; BIOLOGICAL MARKER; CHOLESTEROL; DONEPEZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOSKELETON; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DYSLIPIDEMIA; HUMAN; MEDICAL RESEARCH; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; TREATMENT OUTCOME;

EID: 33749507810     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.08.007     Document Type: Note

References (16)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
4. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
5. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
6. Simons M., Keller P., Dichgans J., and Schulz J.B. Cholesterol and Alzheimer's disease: Is there a link?. Neurology 57 (2001) 1089-1093
7. Das U.N. Statins and the prevention of dementia. CMAJ 165 (2001) 908-909
8. Sparks D.L., Sabbagh M.N., Connor D.J., et al. Atorvastatin for the treatment of mild to moderate alzheimer disease. Arch Neurol 62 (2005) 753-757
9. Rodriguez E.G., Dodge H.H., Birzescu M.A., Stoehr G.P., and Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc 50 (2002) 1852-1856
10. Hajjar I., Schumpert J., Hirth V., Wieland D., and Eleazer G.P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57A (2002) M414-M418
11. Rockwood K., Kirkland S., Hogan D.B., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59 (2002) 223-227
12. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 (2000) 1439-1443
13. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
14. Li G., Higdon R., Kukull W.A., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 (2004) 1624-1628
15. Zandi P.P., Sparks D.L., Khachaturian A.S., et al. Do statins reduce risk of incident dementia and Alzheimer disease?. The Cache County Study. Arch Gen Psychiatry 62 (2005) 217-224
16. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. Journal of Clinical Epidemiology 45 (1992) 197-203